Anais Brasileiros de Dermatologia, Год журнала: 2024, Номер 99(6), С. 895 - 915
Опубликована: Авг. 12, 2024
Atopic dermatitis is a chronic, recurrent, and multifactorial skin-mucosal manifestation resulting from the interaction between elements mainly associated with skin barrier deficit, homeostasis of immune response, neurological aspects, patterns reactivity to environmental antigens, which are established in genetically predisposed individuals. In addition skin, atopic diathesis involves other organs such as airways (upper lower), eyes, digestive tract, neuropsychiatric inflict additional morbidity on dermatological patient. The different phenotypes disease fundamentally depend participation each these factors, life circumstances, age groups, occupational exposure patterns, physical activity, pollution, genetic load, climatic factors. A better understanding complexity its pathogenesis allows not only therapeutic targets but also how identify preponderant that mediate activity circumstance, for selecting best treatment strategies mitigation triggering This narrative review presents an update dermatitis, especially aimed at clinical manifestations, main context available strategies.
Язык: Английский
Процитировано
5Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes
Frontiers in Immunology, Год журнала: 2025, Номер 15
Опубликована: Янв. 10, 2025
OX40, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on surface activated T cells. Upon interaction with its cognate ligand, OX40L, OX40 transmits costimulatory signals to antigen-primed cells, promoting their activation, differentiation, and survival-processes essential for establishment adaptive immunity. Although OX40-OX40L has been extensively studied in context disease treatment, developing substitute naturally membrane-bound particularly multimerized OX40L trimers, that effectively regulates OX40-driven cell responses remains significant challenge. In this study, we successfully engineered soluble OX40L-fusion proteins capable robustly activating This was achieved by incorporating functional multimerization domains into TNF homology domain OX40L. These bound subsequently NF-κB signaling, induced cytokine production cells vitro. vivo, mice treated one proteins-comprising single-chain trimer linked C-terminus human IgG1 Fc domain, forming dimer trimers-exhibited significantly enhanced clonal expansion antigen-specific CD4+ during primary phase immune response. A comparable antibody-fusion protein 4-1BBL, CD70 (CD27L), or GITRL place elicited similar vivo responses. Thus, propose optimizing through innovative design strategies may facilitate development more effective agonists targeted immunotherapies.
Язык: Английский
Процитировано
0Emergency vs. Outpatient Care for Pediatric Atopic Dermatitis: A Population-Based Study of Sociodemographic Factors and Healthcare Utilization
The Journal of Pediatrics, Год журнала: 2025, Номер unknown, С. 114604 - 114604
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0Novel therapeutic receptor agonists and antagonists in allergic conjunctivitis
Current Opinion in Allergy and Clinical Immunology, Год журнала: 2024, Номер 24(5), С. 380 - 389
Опубликована: Июль 22, 2024
Allergic conjunctivitis is characterized by the development of pathophysiological changes to ocular surface, which occurs when pro-allergic and pro-inflammatory mediators interact with their cognate receptors expressed on immune nonimmune cells. Traditional treatments antihistamines corticosteroids provide relief, but there a need for more efficacious tolerable long-term therapy better safety profile. This article aims an overview mode action clinical application agonist therapies targeting glucocorticoid, melanocortin, toll-like receptors, as well antagonist cytokine, chemokine, integrin, histamine receptors.
Язык: Английский
Процитировано
2Race science without racists: how bigoted paradigms persist in allergy research
Frontiers in Public Health, Год журнала: 2024, Номер 12
Опубликована: Июль 10, 2024
In the wake of murder George Floyd and massacre in Buffalo, editorial boards prominent scientific publication companies formally apologized for their journals' historical role advancing race science promised to improve standards. However, flowery commentaries cannot undo consistent pattern endorsing biologic differences between ethnic groups, even when discussing diseases or traits that are not considered politically charged. this report, an exemplar is made a recent claiming identify phenotypes atopic dermatitis distinct European Americans, Asians, African Americans. The insufficiency evidence logic underlying these claims discussed. Although devoid malice, numerous publications continue demonstrate how biological races mainstreamed modern publications. Overall, goal work challenge community, particularly companies, evaluate assumptions innate disadvantage have clouded assessments racial disparities disease beyond topics more stereotypical science.
Язык: Английский
Процитировано
1Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis
Journal of Allergy and Clinical Immunology, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 1, 2024
Amlitelimab, a fully human nondepleting mAb targeting OX40 ligand on antigen-presenting cells, could prevent T-cell-driven inflammation seen in atopic dermatitis (AD). This trial evaluated the efficacy and safety of amlitelimab adults with AD. In this 2-part, phase 2b, randomized, double-blinded placebo-controlled (ClinicalTrials.gov identifier NCT05131477), patients received subcutaneous every 4 weeks at doses 250 mg plus 500-mg loading dose, mg, 125 or 62.5 placebo for 24 Part 1 (1:1:1:1:1 randomization). 2, clinical responders were reallocated 3:1 to stop taking continue previous dose regimen 28 weeks. The primary end point was percentage change Eczema Area Severity Index (EASI) from baseline week 16. all, 390 190 enrolled respectively. A significant decrease EASI observed versus (P < .001). Clinical responses (Investigator Global Assessment 0/1 and/or 75% reduction EASI) maintained 52 continuing stopping amlitelimab. Of maintaining response after no longer receiving treatment, more than 80% had serum concentrations less 4-μg/mL threshold several before 52. Reductions AD-related biomarkers during through 2. Amlitelimab well tolerated over treatment significantly reduced biomarker responses, AD Sustained majority they stopped
Язык: Английский
Процитировано
1Biologic Brachytherapy: Genetically Modified Surgical Flap as a Therapeutic Tool—A Systematic Review of Animal Studies
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(19), С. 10330 - 10330
Опубликована: Сен. 25, 2024
Surgical flaps are rudimentary tools in reconstructive surgery, especially following extensive solid tumour resections. They cover skin and soft tissue defects but prone to ischaemia necrosis. Since their primary aim is reconstruction, they rarely exhibit a therapeutic activity against the treated disease. Attempts have been made develop new strategy—biologic brachytherapy, which uses genetically engineered surgical as drug delivery vehicle, allowing flap act “biologic pump”. This systematic review summarizes preclinical evidence on using modified flaps. A literature search was conducted PubMed, EMBASE, Scopus Web of Science. The initial yielded 714 papers, and, eventually, seventy-seven studies were included qualitative analysis. results show that genetic enhancement has used local or systemic therapy for numerous disease models. Frequently, it increase survival limit promote non-ischemic context, with some focusing optimizing technique such gene therapy. can be successfully variety contexts, we need more implement this research into specific clinical scenarios.
Язык: Английский
Процитировано
0Atualização na patogênese da dermatite atópica
Опубликована: Ноя. 1, 2024
Процитировано
0